ARA-290

Overview

ARA-290, also known as cibinetide or helix-B surface peptide (pHBSP), is a synthetic 11-amino-acid peptide derived from the aqueous-exposed surface of helix B of erythropoietin (EPO). It was developed by researchers led by Anthony Cerami and Michael Brines to exploit a finding that had emerged in the early 2000s: EPO's hematopoietic and tissue-protective effects are mediated by different receptor complexes.

Full-length EPO binds homodimeric EPO receptors (EPOR2) on erythroid progenitors to drive red blood cell production. In tissues such as nerve, brain, kidney, and heart, EPO instead engages a heteromeric receptor composed of EPO receptor monomers and the beta common receptor subunit (CD131) — referred to as the innate repair receptor (IRR). ARA-290 selectively engages the IRR without binding EPOR2, thereby producing tissue-protective and anti-inflammatory effects without erythropoiesis.

This receptor selectivity has made ARA-290 a focus of clinical research in neuropathic pain, sarcoidosis-associated small fiber neuropathy, and diabetic complications, where it has been investigated through intravenous and subcutaneous administration.

Structure / Chemistry

• Sequence (single letter): QEQLERALNSS
• Length: 11 amino acids
• Molecular formula: approximately C55H89N15O20
• Molecular weight: approximately 1257 g/mol
• Origin: Helix B aqueous-face residues of human erythropoietin

ARA-290 is a linear, unmodified peptide without disulfide bonds, glycosylation, or other post-translational modifications. Its small size and lack of glycans distinguish it sharply from full-length glycosylated EPO (30.4 kDa) and contribute to its short plasma half-life but clean receptor selectivity.

Mechanism of Action

ARA-290 acts through the innate repair receptor (IRR), a heteromeric complex of EPOR and the beta common receptor:

• Selective IRR binding without activation of homodimeric EPOR2
• Downstream JAK2/STAT3 and Akt signaling in non-erythroid cells
• Reduction of apoptosis in injured tissue via Bcl-xL upregulation
• Anti-inflammatory effects, including suppression of TNF-alpha, IL-6, and NF-kB pathway activation
• Neurotrophic support of small fiber nerves, with evidence of reinnervation in chronic neuropathy models

Because IRR expression is upregulated at sites of injury and inflammation, ARA-290's activity is spatially concentrated where tissue protection is most relevant. The absence of erythropoietic activity avoids the thrombosis and hypertension risks associated with erythropoiesis-stimulating agents.

Research Summary

Pharmacokinetics

ARA-290 has a very short plasma half-life, on the order of minutes, due to rapid renal filtration and proteolytic degradation. Despite this, its biological effects persist well beyond detectable plasma concentrations, suggesting that a brief IRR engagement is sufficient to trigger sustained intracellular signaling.

The compound has been studied by intravenous and subcutaneous routes. Distribution is broad, with effective engagement of IRR in peripheral nerve, cornea, and inflamed tissue. Elimination is primarily renal.

Common Discussion Topics

• Selectivity between hematopoietic EPOR2 and the innate repair receptor
• Comparison with carbamylated EPO and other non-erythropoietic EPO derivatives
• Clinical research in sarcoid-related small fiber neuropathy
• Potential application in diabetic peripheral neuropathy
• Translational challenges despite compelling mechanistic data

Related Compounds

• EPO — parent molecule from which ARA-290 is derived
• BPC-157 — tissue-protective peptide with overlapping research focus
• Thymosin Beta-4 — cytoprotective peptide
• Humanin — mitochondrial peptide with cytoprotective activity
• Cerebrolysin — neurotrophic peptide preparation

Educational information only. ARA-290 / cibinetide is an investigational peptide not approved for general clinical use. This article does not provide medical or dosing advice.